Literature DB >> 26534926

Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis.

Onno W Akkerman1, Omar F F Odish2, Mathieu S Bolhuis3, Wiel C M de Lange1, Hubertus P H Kremer2, Gert-Jan R Luijckx2, Tjip S van der Werf4, Jan-Willem Alffenaar3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26534926     DOI： 10.1093/cid/civ921

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  12 in total

1.  Radiosynthesis and PET Bioimaging of 76Br-Bedaquiline in a Murine Model of Tuberculosis.

Authors:  Alvaro A Ordonez; Laurence S Carroll; Sudhanshu Abhishek; Filipa Mota; Camilo A Ruiz-Bedoya; Mariah H Klunk; Alok K Singh; Joel S Freundlich; Ronnie C Mease; Sanjay K Jain
Journal:  ACS Infect Dis       Date:  2019-07-29       Impact factor: 5.084

Review 2.  A Scoping Review of the Clinical Pharmacokinetics of Bedaquiline.

Authors:  Kyle J Wilby
Journal:  Clin Pharmacokinet       Date:  2022-01-27       Impact factor: 6.447

3.  Long term outcomes of patients with tuberculous meningitis: The impact of drug resistance.

Authors:  Emily E Evans; Teona Avaliani; Mariam Gujabidze; Tinatin Bakuradze; Maia Kipiani; Shorena Sabanadze; Alison G C Smith; Zaza Avaliani; Jeffrey M Collins; Russell R Kempker
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

4.  Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness.

Authors:  Russell R Kempker; Alison G C Smith; Teona Avaliani; Mariam Gujabidze; Tinatin Bakuradze; Shorena Sabanadze; Zaza Avaliani; Jeffrey M Collins; Henry M Blumberg; Mohammad H Alshaer; Charles A Peloquin; Maia Kipiani
Journal:  Clin Infect Dis       Date:  2022-09-10       Impact factor: 20.999

Review 5.  New Drugs for the Treatment of Tuberculosis.

Authors:  Elisa H Ignatius; Kelly E Dooley
Journal:  Clin Chest Med       Date:  2019-12       Impact factor: 4.967

6.  Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system.

Authors:  Annapurna Pamreddy; Sooraj Baijnath; Tricia Naicker; Sphamandla Ntshangase; Sipho Mdanda; Hlengekile Lubanyana; Hendrik G Kruger; Thavendran Govender
Journal:  RSC Adv       Date:  2018-03-28       Impact factor: 4.036

7.  Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.

Authors:  Shashikant Srivastava; Devyani Deshpande; Jotam Pasipanodya; Eric Nuermberger; Soumya Swaminathan; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2016-11-01       Impact factor: 9.079

Review 8.  Treatment of Tuberculous Meningitis and Its Complications in Adults.

Authors:  Angharad Davis; Graeme Meintjes; Robert J Wilkinson
Journal:  Curr Treat Options Neurol       Date:  2018-02-28       Impact factor: 3.598

9.  A patient with central nervous system tuberculomas and a history of disseminated multi-drug-resistant tuberculosis.

Authors:  Samantha R Kaplan; Jeffrey Topal; Lynn Sosa; Maricar Malinis; Anita Huttner; Ajay Malhotra; Gerald Friedland
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-12-06

10.  Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens.

Authors:  A G C Smith; M Gujabidze; T Avaliani; H M Blumberg; J M Collins; S Sabanadze; T Bakuradze; Z Avaliani; R R Kempker; M Kipiani
Journal:  Int J Tuberc Lung Dis       Date:  2021-08-01       Impact factor: 3.427
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.